Press release
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko
DelveInsight's "Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Urothelial Carcinoma, historical and forecasted epidemiology as well as the Urothelial Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Urothelial Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Urothelial Carcinoma Market Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Urothelial Carcinoma Market Report:
*
The Urothelial Carcinoma market size was valued ~USD 900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In February 2025, Phase I findings for SHR-A2102 in individuals with advanced or metastatic urothelial carcinoma were presented at the 2025 ASCO Genitourinary Cancers Symposium.
*
In December 2024, China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. 's SHR-A2102 has been proposed for designation as a breakthrough therapy. The drug is intended as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have not responded to prior platinum-based chemotherapy and PD-(L)1 inhibitor treatment.
*
In September 2024, The Phase II findings for BL-B01D1 were shared during the 2024 ESMO Congress, highlighting its initial efficacy and safety in patients with locally advanced or metastatic urothelial carcinoma who had received prior treatments.
*
In August 2024, Mabwell Therapeutics, a biopharmaceutical company based in the US, has received authorization from China's National Medical Products Administration (NMPA) to initiate a Phase III clinical trial of 9MW2821 in combination with Toripalimab for the treatment of urothelial carcinoma. This randomized, open-label study will compare the effectiveness of 9MW2821 plus Toripalimab against the investigator's selected chemotherapy as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma.
*
During the forecast period (2024-2034), pipeline candidates like enfortumab vedotin+pembrolizumab plus-minus cisplatin/carboplatin, erdafitinib+cetrelimab, and durvalumab+SoC (cisplatin+gemcitabine/carboplatin+gemcitabine) plus-minus Tremelimumab are expected to contribute to the growth of the UCC market size.
*
In 2023, the United States held the largest share of the UCC market in the 7MM, representing nearly 70% of the market size compared to the EU4, the UK, and Japan.
*
In 2023, the United States reported the highest number of incident UCC cases, representing approximately 40% of the total global cases.
*
Among the EU4 and the UK, Germany had the highest number of UCC cases, followed by Italy, while the UK reported the fewest cases.
*
Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others
*
Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others
*
The Urothelial Carcinoma epidemiology based on gender analyzed that Urothelial carcinoma in males has two-to-three fold greater incidence as compared to females
*
The Urothelial Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Urothelial Carcinoma pipeline products will significantly revolutionize the Urothelial Carcinoma market dynamics.
Urothelial Carcinoma Overview
When the cells that make up the urinary bladder develop into cancer, urothelial carcinoma begins. Any of the four bladder wall layers can give birth to bladder neoplasms. Over 95% of them are considered to be epithelial, while the remaining 5% are non-epithelial (mesenchymal). Urinary carcinomas are epithelial tumors that have differentiated towards normal urothelium.
Get a Free sample for the Urothelial Carcinoma Market Report:
https://www.delveinsight.com/report-store/urothelial-carcinoma-market [https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Urothelial Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Urothelial Carcinoma Epidemiology Segmentation:
The Urothelial Carcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Urothelial Carcinoma
*
Prevalent Cases of Urothelial Carcinoma by severity
*
Gender-specific Prevalence of Urothelial Carcinoma
*
Diagnosed Cases of Episodic and Chronic Urothelial Carcinoma
Download the report to understand which factors are driving Urothelial Carcinoma epidemiology trends @ Urothelial Carcinoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Urothelial Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urothelial Carcinoma market or expected to get launched during the study period. The analysis covers Urothelial Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Urothelial Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Urothelial Carcinoma Therapies and Key Companies
*
KEYTRUDA (pembrolizumab): Merck
*
OPDIVO (nivolumab): Bristol Myers Squibb
*
BT8009: Bicycle Therapeutics
*
Eganelisib + Opdivo: Infinity
*
Infigratinib: QED Therapeutics
*
Tislelizumab: BeiGene
*
Cyramza: Eli Lilly
*
Tecentriq: Roche
*
UGN-102: UroGen
*
Bempegaldesleukin: NektarTherapeutics /BMS
*
Pemazyre (Pemigatinib): Incyte
*
ABSK091/AZD4547: Abbisko
*
Selinexor: Mamta Parikh
*
Tremelimumab: AstraZeneca
*
Erdafitinib: Janssen Research & Development, LLC
*
Niraparib: Pfizer
*
Atezolizumab: Inovio Pharmaceuticals
*
Atezolizumab: Hoffmann-La Roche
*
RC48-ADC: RemeGen Co., Ltd.
Discover more about therapies set to grab major Urothelial Carcinoma market share @ Urothelial Carcinoma Treatment Market [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Urothelial Carcinoma Market Strengths
*
Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of advanced UC market
*
Strong pipeline activity with potential phase III and phase II emerging therapies
*
Presence of several approved therapies for the treatment of urothelial carcinoma patients.
Urothelial Carcinoma Market Opportunities
*
Rising incidence of cancer will provide the larger window of opportunity for new treatments
*
Reoccurrence is very common in cancers even after proper treatment. This opens up new window for pipeline activity
*
Increase in awareness and research of the indication, which provides a clearer aspect regarding potential options for treatment that can be explored by the key players
Scope of the Urothelial Carcinoma Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics /BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others
*
Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others
*
Urothelial Carcinoma Therapeutic Assessment: Urothelial Carcinoma current marketed and Urothelial Carcinoma emerging therapies
*
Urothelial Carcinoma Market Dynamics: Urothelial Carcinoma market drivers and Urothelial Carcinoma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Urothelial Carcinoma Unmet Needs, KOL's views, Analyst's views, Urothelial Carcinoma Market Access and Reimbursement
To know more about Urothelial Carcinoma companies working in the treatment market, visit @ Urothelial Carcinoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Urothelial Carcinoma Market Report Introduction
2. Executive Summary for Urothelial Carcinoma
3. SWOT analysis of Urothelial Carcinoma
4. Urothelial Carcinoma Patient Share (%) Overview at a Glance
5. Urothelial Carcinoma Market Overview at a Glance
6. Urothelial Carcinoma Disease Background and Overview
7. Urothelial Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Urothelial Carcinoma
9. Urothelial Carcinoma Current Treatment and Medical Practices
10. Urothelial Carcinoma Unmet Needs
11. Urothelial Carcinoma Emerging Therapies
12. Urothelial Carcinoma Market Outlook
13. Country-Wise Urothelial Carcinoma Market Analysis (2020-2034)
14. Urothelial Carcinoma Market Access and Reimbursement of Therapies
15. Urothelial Carcinoma Market Drivers
16. Urothelial Carcinoma Market Barriers
17. Urothelial Carcinoma Appendix
18. Urothelial Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=urothelial-carcinoma-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-infinity-qed-therapeutics-beigene-eli-lilly-roche-urogen-nektartherapeutics-bms-incyte-abbisko]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko here
News-ID: 4006259 • Views: …
More Releases from ABNewswire
Desman Orthodontics Launches "Smiles for Students" Scholarship Orthodonist Servi …
For many families in the area, finding a trusted local provider is a priority. As an established orthodontist Port St Lucie families have relied on for years, Desman Orthodontics is uniquely positioned to understand the needs of the community. The practice's decision to create this scholarship stems from a recognition that a healthy, confident smile can have a profound impact on a young person's social development and self-esteem, yet it…
Lone Wolf Roofing Strengthens Its Presence in LaPlace As the Top Roofer in LaPla …
Lone Wolf Roofing is the best roofer in LaPlace Louisiana.
Image: https://www.abnewswire.com/upload/2025/09/d18162e78e8b91dcdbe94df43778e8d2.jpg
Lone Wolf Roofing, a premier Louisiana-based roofing company, today announced the expansion of its services in LaPlace, offering homeowners and businesses access to unmatched craftsmanship, a 100-Year Warranty, and an unprecedented promise: if installation does not begin within 24 hours of signing, the roof is free.
With Louisiana communities facing recurring storms, unpredictable weather, and high roofing costs, Lone Wolf Roofing's…
Family-Owned Meigel Home Innovations Expands Operations to Meet Growing Kitchen …
The decision to expand was driven by a consistent increase in project inquiries over the past several years. "We've seen a fundamental shift," explains a company representative for Meigel Home Improvements. "Homeowners are no longer just fixing a leaky faucet or replacing worn-out countertops. They are undertaking comprehensive transformations. They want a kitchen remodel near me that reflects a modern lifestyle-open-concept layouts, smart storage solutions, and energy-efficient appliances.
HAUPPAUGE, NY -…
Winchester's Powell's Plumbing & Air Launches 24/7 Emergency AC Repair Service A …
The importance of a functional air conditioning system extends beyond mere comfort during a Winchester summer. During heatwaves, indoor temperatures can rise rapidly, creating potentially dangerous conditions for vulnerable populations such as young children, the elderly, and those with certain health conditions. A malfunctioning AC unit can also lead to increased humidity levels inside the home, which may promote mold growth and damage property.
With summer approaching and temperatures predicted to…
More Releases for Urothelial
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Urothelial Cancer Drugs Market for Bladder and Urinary Tract Tumors | Driven by …
Urothelial Cancer Drugs market is expected to grow at a CAGR Of 21.2% during the forecast period 2024-2031.
The Urothelial Cancer Drugs Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm…
Major Market Shift in Urothelial Carcinoma Treatment Industry: Innovations In Ur …
What Is the Forecasted Market Size and Growth Rate for the Urothelial Carcinoma Treatment Market?
In the recent years, there has been a swift escalation in the size of the urothelial carcinoma treatment market. It is projected to expand from $2.86 billion in 2024 to $3.37 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 18.0%. The growth during the past period can be credited to an upsurge in…
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Cancer Drugs Market Emerging Trends 2022-2028
The worldwide urothelial cancer drugs market is supposed to ascend at a strong speed in the following several years with a strong contest among players and the rising instances of harmful diseases. As of now, deft players are seen taking the cooperation course for the improvement of treatments and drugs. Urothelial carcinoma, otherwise called momentary cell carcinoma, is a cancerous growth of the bladder that can spread to different pieces…
